Scholarlink

<p>Antibody drug conjugates (ADCs) are clinically active in several cancers, but their relevance in cholangiocarcinoma (CCA) is undefined. We profiled 23 CCA tumors and found that TROP2 was highly expressed (82.6%) but also present in benign epithelium. NECTIN4 (65.2%) showed tumor-specific staining, supporting selectivity. B7-H3 (47.8%) and CLDN18.2 (13.0%) were less frequently positive. IDH1-mutant tumors demonstrated attenuated ADC target expression. These data provide rationale for evaluating ADC strategies in CCA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月19日

查看全文
  • Mari Nakazawa,
  • Waqar Arif,
  • Ezra Baraban,
  • Andres Matoso,
  • Elsa Hallab,
  • Emma Kartalia,
  • Nilofer S. Azad,
  • Marina Baretti,
  • Daniel J. Zabransky,
  • Robert A. Anders,
  • Kiyoko Oshima,
  • Mark Yarchoan

摘要

Antibody drug conjugates (ADCs) are clinically active in several cancers, but their relevance in cholangiocarcinoma (CCA) is undefined. We profiled 23 CCA tumors and found that TROP2 was highly expressed (82.6%) but also present in benign epithelium. NECTIN4 (65.2%) showed tumor-specific staining, supporting selectivity. B7-H3 (47.8%) and CLDN18.2 (13.0%) were less frequently positive. IDH1-mutant tumors demonstrated attenuated ADC target expression. These data provide rationale for evaluating ADC strategies in CCA.